Hospital
Dignity Health
Dignity Health was paid $133.09M by Medicaid between Jan 2018 and Dec 2024, across 354 billing codes. Its largest line is 0450, Emergency room services — 39% of everything it billed.
33Billing provider infoDIGNITY HEALTH
SAN BERNARDINO, CA 92404
SAN BERNARDINO, CA 92404
33aNPI1689769911assigned 10/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$133.09M
24GClaims2,345,963
24DCodes billed354
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#12 of 410
Median peer was paid$6.90M
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORISSETTE, DANIEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 375,312 | $20.08M | |
| 2019 | 406,249 | $22.28M | |
| 2020 | 301,365 | $16.69M | |
| 2021 | 314,844 | $18.68M | |
| 2022 | 355,927 | $22.57M | |
| 2023 | 394,974 | $23.76M | |
| 2024incomplete | 197,292 | $9.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 39% | 142,077 | 121,652 | $52.46M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 73,557 | 64,063 | $30.23M |
| 0456 | 13% | 143,351 | 129,837 | $17.12M | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.2% | 76,659 | 70,105 | $9.54M |
| Z7502 | 1.0% | 35,715 | 34,874 | $1.35M | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 346 | 340 | $1.18M |
| 0360 | <1% | 6,917 | 3,074 | $1.14M | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 17,463 | 17,208 | $1.08M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | <1% | 11,034 | 10,305 | $1.05M |
| G0378 | Hospital observation service, per hour | <1% | 5,385 | 3,811 | $1.03M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 18,852 | 18,022 | $921K |
| 99070 | <1% | 149,842 | 83,525 | $877K |
342 more codes
| 99285 | Emergency room visit (most serious) | <1% | 8,687 | $840K |
| 0762 | <1% | 5,423 | $714K | |
| 93454 | <1% | 804 | $603K | |
| Z7500 | <1% | 16,824 | $573K | |
| 99499 | <1% | 9,770 | $553K | |
| 99221 | <1% | 2,665 | $483K | |
| J3490 | Unclassified drugs | <1% | 127,090 | $478K |
| 80053 | Comprehensive metabolic panel | <1% | 95,376 | $439K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 9,528 | $428K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 31,797 | $427K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 25,026 | $391K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 15,671 | $352K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 9,398 | $310K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 59,130 | $304K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 62,747 | $258K |
| 0710 | <1% | 3,865 | $251K | |
| 0949 | <1% | 1,622 | $227K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 4,081 | $214K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 108,912 | $213K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 10,064 | $211K |
| 0720 | <1% | 4,801 | $193K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 2,574 | $188K |
| 71045 | Radiologic examination, chest; single view | <1% | 44,744 | $179K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,487 | $165K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,542 | $160K |
| 0370 | <1% | 1,305 | $157K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 23,468 | $144K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,324 | $140K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,601 | $130K |
| 97750 | <1% | 2,962 | $130K | |
| 59025 | Fetal non-stress test | <1% | 3,295 | $110K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 2,538 | $109K |
| 0760 | <1% | 2,892 | $102K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,232 | $97K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,007 | $97K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,158 | $95K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,748 | $95K |
| 97139 | <1% | 3,258 | $95K | |
| Z7610 | <1% | 19,168 | $93K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 18,461 | $92K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,081 | $89K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,356 | $89K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 7,777 | $88K |
| C1747 | Endoscope, single-use (i.e. disposable), urinary tract, imaging/illumination device (insertable) | <1% | 25 | $87K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,050 | $87K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 942 | $84K |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,555 | $83K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,578 | $80K |
| C1769 | Guide wire | <1% | 1,185 | $80K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 187 | $75K |
| 99218 | <1% | 422 | $75K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,947 | $75K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,092 | $74K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,693 | $71K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,055 | $66K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,125 | $60K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,846 | $58K |
| 82962 | <1% | 31,167 | $53K | |
| 84484 | <1% | 34,485 | $53K | |
| 93971 | <1% | 2,915 | $53K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,385 | $52K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,988 | $51K |
| 0001A | <1% | 1,351 | $49K | |
| 92588 | <1% | 857 | $48K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 13 | $47K |
| C1781 | Mesh (implantable) | <1% | 44 | $47K |
| 76801 | <1% | 4,361 | $47K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,609 | $46K |
| 87081 | <1% | 9,619 | $46K | |
| 0002A | <1% | 1,192 | $46K | |
| 94729 | <1% | 756 | $44K | |
| 83880 | <1% | 10,769 | $43K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,628 | $42K |
| 81001 | <1% | 52,312 | $41K | |
| 94060 | <1% | 998 | $40K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 2,165 | $40K |
| 47562 | <1% | 129 | $40K | |
| 0250 | <1% | 7,967 | $39K | |
| 52356 | <1% | 222 | $39K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 41,634 | $37K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,183 | $36K |
| 99199 | Unlisted special service, procedure or report | <1% | 184 | $36K |
| 0459 | <1% | 1,319 | $36K | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,474 | $34K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,205 | $34K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 12,291 | $32K |
| 88307 | <1% | 878 | $32K | |
| 70486 | <1% | 1,669 | $31K | |
| 85730 | <1% | 11,603 | $30K | |
| 86900 | <1% | 8,279 | $30K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 28,950 | $29K |
| 83690 | <1% | 29,836 | $28K | |
| 99224 | <1% | 376 | $28K | |
| 90715 | <1% | 5,007 | $28K | |
| 72131 | <1% | 1,239 | $28K | |
| 94727 | <1% | 728 | $28K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 27,539 | $27K |
| 99152 | <1% | 476 | $26K | |
| Z9725 | <1% | 606 | $26K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,085 | $25K |
| V5008 | Hearing screening | <1% | 463 | $25K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,093 | $25K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 18,755 | $25K |
| 81003 | <1% | 43,660 | $24K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,207 | $24K |
| 93970 | <1% | 707 | $24K | |
| 85610 | <1% | 14,524 | $23K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,429 | $23K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,141 | $22K |
| 73130 | <1% | 6,268 | $21K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,499 | $21K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 268 | $21K |
| 73630 | <1% | 6,227 | $21K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 16,440 | $21K |
| 73610 | <1% | 5,848 | $20K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,374 | $20K |
| 73030 | <1% | 4,408 | $20K | |
| 88304 | <1% | 1,427 | $19K | |
| 86850 | <1% | 4,407 | $19K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 499 | $18K |
| 70496 | <1% | 452 | $17K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 68 | $17K |
| 73562 | <1% | 4,115 | $17K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,808 | $16K |
| 81025 | <1% | 18,331 | $16K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 200 | $16K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 14,250 | $16K |
| 82803 | <1% | 2,915 | $16K | |
| C1758 | Catheter, ureteral | <1% | 568 | $15K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 670 | $15K |
| 99217 | <1% | 394 | $14K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,899 | $14K |
| 99225 | <1% | 173 | $14K | |
| 73110 | <1% | 3,754 | $14K | |
| 83605 | <1% | 9,520 | $13K | |
| 84702 | <1% | 6,840 | $13K | |
| 74018 | <1% | 2,030 | $12K | |
| 85027 | <1% | 4,225 | $12K | |
| 87040 | <1% | 6,308 | $12K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 7,698 | $12K |
| 0270 | <1% | 3,061 | $12K | |
| 0761 | <1% | 449 | $11K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,541 | $11K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,777 | $11K |
| 74240 | <1% | 98 | $11K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,948 | $11K |
| 73564 | <1% | 1,981 | $11K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,284 | $11K |
| 71250 | <1% | 260 | $10K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,007 | $10K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,062 | $10K |
| 87077 | <1% | 6,405 | $10K | |
| 12001 | <1% | 2,701 | $10K | |
| 72128 | <1% | 254 | $10K | |
| 93458 | <1% | 13 | $10K | |
| 70498 | <1% | 489 | $10K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 8,509 | $9K |
| 87186 | <1% | 5,773 | $9K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,245 | $9K |
| 12002 | <1% | 1,089 | $9K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 312 | $9K |
| 76870 | <1% | 657 | $9K | |
| 72100 | <1% | 2,486 | $8K | |
| 87210 | <1% | 4,741 | $8K | |
| 73080 | <1% | 2,254 | $8K | |
| A9270 | Non-covered item or service | <1% | 14,571 | $8K |
| 70491 | <1% | 176 | $8K | |
| 71101 | <1% | 901 | $8K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,622 | $7K |
| 84703 | <1% | 1,969 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,905 | $7K |
| 88313 | <1% | 237 | $7K | |
| 73590 | <1% | 2,170 | $7K | |
| 73090 | <1% | 1,855 | $7K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 139 | $7K |
| 76770 | <1% | 412 | $7K | |
| 83735 | <1% | 5,967 | $7K | |
| 86780 | <1% | 2,297 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,911 | $6K |
| 73502 | <1% | 1,507 | $6K | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 1,814 | $6K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 41 | $6K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,815 | $6K |
| 10060 | <1% | 1,524 | $6K | |
| 93976 | <1% | 130 | $6K | |
| 87631 | <1% | 862 | $6K | |
| 72040 | <1% | 1,179 | $5K | |
| 0004A | <1% | 130 | $5K | |
| 12011 | <1% | 1,661 | $5K | |
| 36600 | <1% | 514 | $5K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 364 | $5K |
| 72132 | <1% | 118 | $5K | |
| 74174 | <1% | 50 | $4K | |
| 73140 | <1% | 1,950 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,286 | $4K |
| 87070 | <1% | 1,020 | $4K | |
| 29515 | <1% | 1,050 | $4K | |
| 29125 | <1% | 1,552 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,407 | $4K |
| 49083 | <1% | 24 | $4K | |
| 82248 | <1% | 1,074 | $4K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 132 | $4K |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 185 | $3K |
| 86901 | <1% | 4,609 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,617 | $3K |
| 82247 | <1% | 1,026 | $3K | |
| 86141 | <1% | 1,876 | $3K | |
| 71020 | <1% | 279 | $3K | |
| 84145 | <1% | 1,238 | $3K | |
| 49650 | <1% | 12 | $3K | |
| 80061 | Lipid panel | <1% | 1,022 | $3K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 447 | $2K |
| 84100 | <1% | 3,133 | $2K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 27 | $2K |
| 99234 | <1% | 294 | $2K | |
| 82550 | <1% | 2,374 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 860 | $2K |
| 0272 | <1% | 872 | $2K | |
| 85379 | <1% | 1,977 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,362 | $2K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 107 | $2K |
| 72129 | <1% | 71 | $2K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 84 | $2K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 478 | $2K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 791 | $2K |
| 83615 | <1% | 491 | $2K | |
| 87205 | <1% | 768 | $2K | |
| 73060 | <1% | 503 | $2K | |
| 0054A | <1% | 47 | $2K | |
| 73620 | <1% | 647 | $2K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 300 | $2K |
| 87400 | <1% | 1,174 | $2K | |
| 82140 | <1% | 1,265 | $2K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 150 | $2K |
| 82365 | <1% | 53 | $2K | |
| 73600 | <1% | 340 | $2K | |
| 84132 | <1% | 771 | $2K | |
| 80076 | <1% | 1,257 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,424 | $1K |
| 96376 | <1% | 1,549 | $1K | |
| 88342 | <1% | 55 | $1K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 53 | $1K |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 128 | $1K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 109 | $1K |
| 73552 | <1% | 367 | $1K | |
| 93017 | <1% | 85 | $1K | |
| 11045 | <1% | 30 | $1K | |
| 84439 | <1% | 1,281 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,455 | $1K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,167 | $1K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 669 | $987.02 |
| 97162 | <1% | 74 | $963.08 | |
| 73100 | <1% | 177 | $939.84 | |
| 97799 | <1% | 82 | $905.82 | |
| 82731 | <1% | 14 | $898.10 | |
| 0301 | <1% | 158 | $895.30 | |
| 86803 | <1% | 271 | $885.81 | |
| 29105 | <1% | 439 | $828.11 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 950 | $822.41 |
| 93350 | <1% | 13 | $773.97 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 466 | $730.46 |
| 97165 | <1% | 35 | $673.27 | |
| 88300 | <1% | 209 | $624.23 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 13 | $622.21 |
| 73120 | <1% | 234 | $583.27 | |
| 80074 | <1% | 126 | $558.94 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 430 | $554.93 |
| 85652 | <1% | 1,524 | $523.78 | |
| 0052A | <1% | 13 | $520.00 | |
| 90658 | <1% | 44 | $519.31 | |
| 92950 | <1% | 48 | $494.88 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 243 | $493.55 |
| 73560 | <1% | 97 | $488.79 | |
| 85384 | <1% | 57 | $486.50 | |
| 0031A | <1% | 12 | $480.00 | |
| 82010 | <1% | 642 | $474.39 | |
| 82553 | <1% | 377 | $459.49 | |
| 80185 | <1% | 64 | $441.87 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 317 | $422.79 |
| 73070 | <1% | 124 | $422.63 | |
| 97597 | <1% | 17 | $421.10 | |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | <1% | 136 | $415.82 |
| 85007 | <1% | 889 | $389.91 | |
| 87147 | <1% | 252 | $382.38 | |
| 72070 | <1% | 103 | $375.05 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 12 | $360.91 |
| 71010 | <1% | 198 | $342.47 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12 | $341.40 |
| 80299 | <1% | 40 | $318.40 | |
| 10061 | <1% | 121 | $315.59 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 14 | $312.01 |
| 69209 | <1% | 724 | $292.02 | |
| 82570 | <1% | 60 | $291.84 | |
| 97164 | <1% | 50 | $272.23 | |
| 84550 | <1% | 83 | $250.57 | |
| 72072 | <1% | 68 | $212.85 | |
| 72170 | <1% | 42 | $200.02 | |
| 96367 | <1% | 99 | $199.79 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 24 | $183.18 |
| 73660 | <1% | 72 | $167.22 | |
| 87529 | <1% | 25 | $161.68 | |
| 87632 | <1% | 12 | $154.59 | |
| 87340 | <1% | 42 | $154.13 | |
| 74022 | <1% | 42 | $152.13 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 15 | $136.00 |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 32 | $129.79 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 92 | $126.96 |
| 82728 | <1% | 63 | $122.47 | |
| 84156 | <1% | 31 | $115.18 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 36 | $110.31 |
| 86592 | <1% | 188 | $103.25 | |
| 87420 | <1% | 271 | $100.37 | |
| 76802 | <1% | 39 | $100.22 | |
| 81002 | <1% | 645 | $80.18 | |
| 70360 | <1% | 60 | $74.37 | |
| 96368 | <1% | 29 | $70.09 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 49 | $59.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 68 | $49.23 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 21 | $48.00 |
| 51702 | <1% | 103 | $40.74 | |
| 31500 | <1% | 37 | $35.86 | |
| 86694 | <1% | 40 | $27.00 | |
| 80164 | <1% | 14 | $24.84 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 14 | $20.26 |
| 82607 | <1% | 14 | $19.30 | |
| 82746 | <1% | 14 | $18.82 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 34 | $14.88 |
| 11730 | <1% | 24 | $14.34 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 19 | $11.83 |
| 29530 | <1% | 41 | $8.61 | |
| 84436 | <1% | 37 | $6.56 | |
| 29126 | <1% | 31 | $6.05 | |
| 0306 | 0% | 73 | $0.00 | |
| 0307 | 0% | 25 | $0.00 | |
| 0324 | 0% | 24 | $0.00 | |
| 0305 | 0% | 88 | $0.00 | |
| 0352 | 0% | 15 | $0.00 | |
| 0420 | 0% | 15 | $0.00 | |
| 0300 | 0% | 88 | $0.00 | |
| 69200 | 0% | 12 | $0.00 | |
| 0730 | 0% | 15 | $0.00 | |
| 91300 | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORISSETTE, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Dignity Health | Phoenix, AZ | $126.19M |
| Dignity Health | Bakersfield, CA | $109.22M |
| Dignity Health | Merced, CA | $106.54M |
| Dignity Health | Carmichael, CA | $97.28M |
| Dignity Health | Oxnard, CA | $96.24M |
| Dignity Health | Redding, CA | $92.21M |
| Dignity Health | Long Beach, CA | $59.98M |
| Dignity Health | Sacramento, CA | $45.52M |
| Dignity Health | Folsom, CA | $45.14M |
| Dignity Health | Red Bluff, CA | $39.92M |
| Dignity Health | Santa Cruz, CA | $33.59M |
| Dignity Health | Gilbert, AZ | $28.49M |
| Dignity Health | Glendale, AZ | $26.30M |
| Dignity Health | Henderson, NV | $18.73M |
| Dignity Health | Mount Shasta, CA | $15.62M |
| Dignity Health | Henderson, NV | $8.52M |
| Dignity Health | Las Vegas, NV | $7.93M |
| Dignity Health | Camarillo, CA | $6.31M |
| Dignity Health | Santa Maria, CA | $5.79M |
| Dignity Health | Corning, CA | $3.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.